These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1880 related items for PubMed ID: 18759925

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Targeting costimulatory pathways for tumor immunotherapy.
    Ward RC, Kaufman HL.
    Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
    [Abstract] [Full Text] [Related]

  • 3. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
    Wolchok JD, Saenger Y.
    Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
    [Abstract] [Full Text] [Related]

  • 4. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
    Korman A, Yellin M, Keler T.
    Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. How the immune system achieves self-nonself discrimination during adaptive immunity.
    Jiang H, Chess L.
    Adv Immunol; 2009 Jun; 102():95-133. PubMed ID: 19477320
    [Abstract] [Full Text] [Related]

  • 7. From cancer immunosurveillance to cancer immunotherapy.
    Stagg J, Johnstone RW, Smyth MJ.
    Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA, Hu P, Epstein AL.
    Handb Exp Pharmacol; 2008 Dec; (181):291-328. PubMed ID: 18071951
    [Abstract] [Full Text] [Related]

  • 11. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
    Cheuk AT, Mufti GJ, Guinn BA.
    Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily.
    Peggs KS, Allison JP.
    Br J Haematol; 2005 Sep; 130(6):809-24. PubMed ID: 16156851
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
    Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J.
    Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
    Habib-Agahi M, Phan TT, Searle PF.
    Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
    [Abstract] [Full Text] [Related]

  • 20. The B7 family and cancer therapy: costimulation and coinhibition.
    Zang X, Allison JP.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5271-9. PubMed ID: 17875755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 94.